Gossamer Bio (STU:4GB) Retained Earnings : €-1,211.5 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gossamer Bio Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Gossamer Bio's retained earnings for the quarter that ended in Dec. 2024 was €-1,211.5 Mil.

Gossamer Bio's quarterly retained earnings increased from Jun. 2024 (€-1,119.2 Mil) to Sep. 2024 (€-1,113.2 Mil) but then declined from Sep. 2024 (€-1,113.2 Mil) to Dec. 2024 (€-1,211.5 Mil).

Gossamer Bio's annual retained earnings declined from Dec. 2022 (€-974.4 Mil) to Dec. 2023 (€-1,111.4 Mil) and declined from Dec. 2023 (€-1,111.4 Mil) to Dec. 2024 (€-1,211.5 Mil).

Gossamer Bio Retained Earnings Historical Data

The historical data trend for Gossamer Bio's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Retained Earnings Chart

Gossamer Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

-474.73

-718.21

-974.42

-1,111.44

-1,211.48

Gossamer Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial															-1,111.44	-1,153.65	-1,119.20	-1,113.22	-1,211.48

Gossamer Bio Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Gossamer Bio (STU:4GB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Gossamer Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (STU:4GB) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

GOSS:USA 4GB:Germany

Address

3115 Merryfield Row, Suite 120, San Diego, CA, USA, 92121

Website

https://www.gossamerbio.com

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Gossamer Bio Headlines

No Headlines